ISRCTN64282813已完成不适用
Pilot, open-label, prospective, longitudinal, parallel study to evaluate the effect of chondroitin sulfate treatment effect in synovitis measured by ultrasonography in knee osteoarthritis patients
Hospital del Mar (Spain)0 个研究点目标入组 70 人开始时间: 2014年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Men or women 40 years or older
- •2. Fulfilment of the American College of Rheumatology (ACR) classification criteria for clinical KOA
- •3. Presence of radiographic OA in the knee joint, defined as a Kellgren and Lawrence (K&L) score of 2 or 3.
- •4. Ultrasonography presence of synovitis plus joint effusion thickness =4 mm
排除标准
- •1. Any serious disease (such as decompensate heart disease, diabetes, fibromyalgia, renal insufficiency, liver disease or malignancies)
- •2. Secondary OA
- •3. Use of any medication already know to affect the variables examined (oral corticosteroids, intra-articular corticosteroids, or any SYSADOA within 3 previous months before study enrolment, or any nonsteroidal anti-inflammatory drug within 30 days before study?s enrolment)
研究者
相似试验
已完成
不适用
Study to evaluate the clinical effect of chondroitin sulfate as adjunctive therapy in periodontitis diseasePeriodontitisISRCTN15683590Rheumatology Service, Hospital del Mar20
进行中（未招募）
1 期
A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapyin preventing the evolution of proliferative lesions assessed by renal biopsy in patients with extracapillary glomerulonephritisEUCTR2015-003884-12-ITAZIENDA OSPEDALIERA PAPA GIOVANNI XXIII22
已完成
2 期
Antibiotic drop instillation during continuous contact lens wear.ACTRN12608000626369CIBA VISION Corporation40
进行中（未招募）
1 期
Phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared with Everolimus in patients with inoperable, progressive, neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)MedDRA version: 20.0Level: PTClassification code 10077559Term: Gastroenteropancreatic neuroendocrine tumour diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001897-13-NLITM Solucin GmbH300
进行中（未招募）
1 期
Phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared with Everolimus in patients with inoperable, progressive, neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)MedDRA version: 20.0Level: PTClassification code 10077559Term: Gastroenteropancreatic neuroendocrine tumour diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001897-13-ATITM Solucin GmbH300